IMNN
Imunon, Inc.
Key Financials
Revenue
$500000
0.0%
Net Income
$-14495028
↑ 22.2%
Operating Income
$-14650694
↑ 23.4%
Total Liabilities
$5.2M
↓ 4.5%
EPS (Diluted)
$-6.83
↓ 321.6%
Shareholders' Equity
$7.1M
↑ 66.4%
Long-term Debt
$6.0M
↑ 1.9%
Cash & Equivalents
$8.8M
↑ 49.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 10/13/2026 | View on SEC |
| 4 | 10/13/2026 | View on SEC |
| 4 | 10/13/2026 | View on SEC |
| 8-K | 9/29/2026 | View on SEC |
| 4 | 9/28/2026 | View on SEC |
| 4 | 9/28/2026 | View on SEC |
| 4 | 9/28/2026 | View on SEC |
| 4 | 9/15/2026 | View on SEC |
| 4 | 9/15/2026 | View on SEC |
| 4 | 9/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IMNN |
| Company Name | Imunon, Inc. |
| CIK | 749647 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (609) 896-9100 |